DALLAS, July 22, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock report featuring Oncothyreon Inc. (Nasdaq:ONTY). The report briefly notes the company's most recent developments and news, and outlines its financial position, market performance, and comparison against industry peers.
The full report is available at: www.microstockprofit.com/lp/ONTY
Oncothyreon Inc. (ONTY) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. ONTY's lead product candidate is Stimuvax, a cancer vaccine in phase III development for non-small cell lung cancer (NSCLC). ONTY has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany, for the development, manufacture and commercialization of Stimuvax.
This newsletter has been helping traders make great investment decisions on ONTY; click here for a 25% discount offer.
In the report, the analyst notes:
"Shares of ONTY rallied more than 15% on Wednesday after a report suggested that the small-cap cancer drug developer could report a successful phase III trial of Stimuvax, which is indicated for stage 3 non-small cell lung cancer."
"ONTY reported a net loss from operations of $5.9 million for the first quarter of 2011, up from $5.4 million in the first quarter of 2010. The Company attributed the result to increased research and development expenses, offset by a decrease in general and administrative expenses."
To read the entire report visit: www.microstockprofit.com/lp/ONTY
See what investors are saying about ONTY at http://www.stockhideout.com
Get breaking news on ONTY at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.